论文部分内容阅读
目的探讨曲妥珠单抗联合不同化疗方案治疗人表皮生子因子受体2(Her-2)阳性晚期乳腺癌的疗效和安全性。方法选取2013年1月—2015年12月我院收治的Her-2阳性晚期乳腺癌患者60例,随机分为对照组和研究组各30例,对照组使用常规化疗方案,研究组在常规化疗基础上联合使用曲妥珠单抗治疗。结果研究组患者RR以及DCR率高于对照组患者,差异有统计学意义(P<0.05),两组患者不良反应对比差异无统计学意义(P>0.05)。结论曲妥珠单抗联合化疗方法治疗HER-2阳性晚期乳腺癌患者,可以显著改善治疗效果,并且安全可靠。
Objective To investigate the efficacy and safety of trastuzumab combined with different chemotherapy regimens in the treatment of Her-2-positive advanced breast cancer. Methods Sixty patients with Her-2-positive advanced breast cancer admitted to our hospital from January 2013 to December 2015 were randomly divided into control group and study group, with 30 cases in each group. Patients in control group were treated with routine chemotherapy, Based on the combination of trastuzumab treatment. Results The RR and DCR rate in study group were higher than those in control group, the difference was statistically significant (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion Trastuzumab combined with chemotherapy for HER-2-positive patients with advanced breast cancer can significantly improve the treatment effect and is safe and reliable.